BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26206899)

  • 21. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
    Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
    Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia.
    Bian J; Shao H; Liu H; Li H; Fang L; Xing C; Wang L; Tao M
    Reprod Sci; 2015 Jun; 22(6):758-66. PubMed ID: 25536958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
    Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
    Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
    Haoula ZJ; Walker KF; Powell MC
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
    Dolapcioglu K; Boz A; Baloglu A
    Clin Exp Obstet Gynecol; 2013; 40(1):122-6. PubMed ID: 23724525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia.
    Qi X; Zhao W; Duan Y; Li Y
    Gynecol Obstet Invest; 2008; 65(4):266-8. PubMed ID: 18196936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
    El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
    Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy.
    Gallos ID; Ganesan R; Gupta JK
    Obstet Gynecol; 2013 Jun; 121(6):1165-1171. PubMed ID: 23812448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
    Wan YL; Holland C
    Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.
    Ewies AA; Alfhaily F
    Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignant endometrial polyp in woman with the levonorgestrel intrauterine system - a case report.
    Kuzel D; Mara M; Zizka Z; Koliba P; Dundr P; Fanta M
    Gynecol Endocrinol; 2019 Feb; 35(2):112-114. PubMed ID: 30449212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis.
    Elassall GM; Sayed EG; Abdallah NA; El-Zohiry MM; Radwan AA; AlMahdy AM; Sedik AS; Elazeem HASA; Shazly SA
    J Gynecol Obstet Hum Reprod; 2022 Oct; 51(8):102432. PubMed ID: 35760334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia.
    van der Meer AC; Hanna LS
    Clin Obes; 2017 Feb; 7(1):54-57. PubMed ID: 27984850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced endometrial cancer following the insertion of the levonorgestrel-releasing intrauterine system in a 34-year-old woman: A case report.
    Jiang J; Du H; Peng H
    Contraception; 2020 Dec; 102(6):428-429. PubMed ID: 32860769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
    Kresowik J; Ryan GL; Van Voorhis BJ
    Obstet Gynecol; 2008 Feb; 111(2 Pt 2):547-9. PubMed ID: 18239018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia.
    Behnamfar F; Ghahiri A; Tavakoli M
    J Res Med Sci; 2014 Aug; 19(8):686-90. PubMed ID: 25422650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.